sj-docx-1-tab-10.1177_1759720X211033679 – Supplemental material for Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis

Supplemental material, sj-docx-1-tab-10.1177_1759720X211033679 for Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis by Cosimo Bruni, Stefano Gentileschi, Giovanni Pacini, Marco Bardelli, Lorenzo Tofani, Francesca Bartoli, Caterina Baldi, Laura Cometi, Ginevra Fiori, Francesca Nacci, Luca Cantarini, Serena Guiducci, Alberto Moggi-Pignone, Bruno Frediani and Marco Matucci-Cerinic in Therapeutic Advances in Musculoskeletal Disease